Company Tryp Therapeutics Inc. OTC Markets

Equities

TRYPF

CA89854F1062

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:06:05 2024-04-29 pm EDT			5-day change	1st Jan Change
0.0476 ^USD	-2.76%		+32.50%	+39.88%

Mar. 08	Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding	CI
Feb. 05	Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Tryp Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Companyâs lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The Company's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience.

Managers	Title	Age	Since
Jason Carroll CEO	Chief Executive Officer	-	23-09-30
James Kuo FOU	Founder	58	19-09-23
James O’Neill DFI	Director of Finance/CFO	64	22-09-18
James Gilligan PSD	President	72	20-10-31
Sidney Taubenfeld COO	Chief Operating Officer	-	22-06-22
Michael Silverman CTO	Chief Tech/Sci/R&D Officer	-	-
Peter Guzzo PRN	Corporate Officer/Principal	-	20-12-21
Peter Molloy PRN	Corporate Officer/Principal	52	20-09-24

Members of the board	Title	Age	Since
James Kuo FOU	Founder	58	19-09-23
Peter Molloy PRN	Corporate Officer/Principal	52	20-09-24
Christopher Ntoumenopoulos BRD	Director/Board Member	-	22-05-24
Gage Jull CHM	Chairman	64	20-09-24

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	96,419,347	94,755,518 ( 98.27 %)	0	98.27 %

Name	Equities	%	Valuation
Garner William 39.85 %	38,420,000	39.85 %	691 560 $
James Kuo 6.223 %	6,000,000	6.223 %	108 000 $
Gage Jull 0.4811 %	463,829	0.4811 %	8 349 $
Peter Molloy 0.2074 %	200,000	0.2074 %	3 600 $
Jason Carroll 0.000337 %	325	0.000337 %	6 $
Sobol Capital Pty Ltd. 0.000104 %	100	0.000104 %	2 $
James Gilligan 0.000000 %	0	0.000000 %	- $
Christopher Ntoumenopoulos 0.000000 %	0	0.000000 %	- $
James O’Neill 0.000000 %	0	0.000000 %	- $

Tryp Therapeutics, Inc.

1665 Ellis Street Suite 301

V1Y 2B3, Kelowna

+833-811-8797

http://tryptherapeutics.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.06

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research